Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma

Abstract

AIM:To verify that CD markers are available for detecting cancer stem cell populations and to evaluate their clinical significance in colon cancer. METHODS:Immunohistochemistry for CD133, CD24 and CD44 was performed on the tissue microarray of 523 colorectal adenocarcinomas. Medical records were reviewed and clinicopathological analysis was performed. RESULTS:In colorectal adenocarcinoma, 128 of 523 cases (24.5%) were positive and 395 cases (75.5%) were negative for CD133 expression. Two hundred and sixty-four of 523 cases (50.5%) were positive and 259 cases (49.5%) were negative for CD24 expression. Five hundred and two of 523 cases (96%) were negative and 21 cases (4%) were positive for CD44 expression. Upon clinicopathological analysis, CD133 expression was present more in male patients (P = 0.002) and in advanced T stage cancer (P = 0.024). Correlation between CD24 expression and clinicopathological factors was seen in the degree of differentiation (P = 0.006). Correlation between CD44 expression and clinicopathological factors was seen in the tumor size (P = 0.001). Survival was not significantly related to CD133, CD24 and CD44 expression. C O N C L U S I O N :C D m a r k e r s w e r e r e l a t e d t o invasiveness and differentiation of colorectal adenocarcinoma. However, CD expression was not closely related to survival.

ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder

“…CD44, a specific receptor for hyaluronic acid and adhesion/homing molecule (Naor et al, 2008;Jaggupilli and Elkord, 2012), is a multifunctional class I transmembrane glycoprotein expressed in almost all normal and cancer cells (Naor et al, 2008;Jaggupilli and Elkord, 2012). In several previous studies, CD44 individually or in combination with other putative CSC markers has been applied to isolate CSCs in various solid tumors including breast (Al-Hajj et al, 2003), prostate, pancreas (Immervoll et al, 2011), ovarian, colorectal (Wielenga et al, 1993;Woodman et al, 1996;Choi et al, 2009), head and neck (Satpute et al, 2013) and bladder cancers (Yang and Chang, 2008;Chan et al, 2009;Slomiany et al, 2009;Lee et al, 2010;Su et al, 2010;Jaggupilli and Elkord, 2012). Both in vitro and in vivo studies have shown that CD44+ bladder cancer cells have higher tumorigenic potential compared to CD44-bladder cancer cells; whereas they have lower tumorigenic potential compared to ALDH1A1+ cells .…”

The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases

“…CD44 expression is found to predict a worsened OS (13), as is CD24 (14). However, another group found no relation between the expression of any of these markers and survival after colon cancer treatment, whilst they did conclude CD133 and CD24 to be correlated with invasiveness and differentiation (28).…”

Clinicopathological significance and prognostic value of leukemia‐related protein 16 expression in invasive ductal breast carcinoma

“…(33) There is no report on CD133 expression in the prognosis of invasive ductal breast carcinoma. Like the significance of CD133, (18)(19)(20)(21)(22)(23)(24)(25) we have also recently reported (7) that LRP16 is a prognostic factor in colorectal cancer. It is interesting to explore the correlation between CD133 and LRP16 in invasive ductal breast carcinoma.…”

“…However, the authors did not perform the survival analysis by follow up. CD133 expression as a prognostic marker has been found in colorectal cancer (18)(19)(20)(21)(22)(23)(24)(25) and brain tumors, (26)(27)(28) but it is still unclear if CD133 can be used as a prognostic marker in pancreatic cancer, (29) ovarian cancer,hepatocellular cancer (31,32) and non-small cell lung carcinoma.(33) There is no report on CD133 expression in the prognosis of invasive ductal breast carcinoma. Like the significance of CD133, (18)(19)(20)(21)(22)(23)(24)(25) we have also recently reported (7) that LRP16 is a prognostic factor in colorectal cancer.…”

“…However, the authors did not perform the survival analysis by follow up. CD133 expression as a prognostic marker has been found in colorectal cancer (18)(19)(20)(21)(22)(23)(24)(25) and brain tumors, (26)(27)(28) but it is still unclear if CD133 can be used as a prognostic marker in pancreatic cancer, (29) ovarian cancer,…”